Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | MVD | P53602 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | BHMT | Q93088 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | CES1 | P23141 | 5/20 | 0.37 |
| ▸ | FAAH | O00519 | 4/20 | 0.37 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.37 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22922079 | 0.98 | GMNN (0.61) | GMNNTP53POLBMAPTTHRB | |
| SCHEMBL29313355 | 0.89 | GMNN (0.61) | GMNNTP53POLBMAPTTHRB | |
| SCHEMBL23733922 | 0.86 | GMNN (0.49) | GMNNTP53POLBMAPTTHRB | |
| SCHEMBL8666564 | 0.85 | HSD17B10 (0.73) | GMNNTP53POLBMAPTTHRB | |
| SCHEMBL22922013 | 0.83 | HSD17B10 (0.70) | GMNNTP53POLBMAPTTHRB | |
| Hydrochloric Acid SCHEMBL11144143 | 0.83 | HSD17B10 (0.70) | GMNNTP53POLBMAPTTHRB | |
| SCHEMBL5597990 | 0.83 | HSD17B10 (0.77) | GMNNTP53POLBMAPTTHRB | |
| SCHEMBL6231607 | 0.83 | HSD17B10 (0.77) | GMNNTP53POLBMAPTTHRB | |
| SCHEMBL2807324 | 0.83 | HSD17B10 (0.77) | GMNNTP53POLBMAPTTHRB | |
| SCHEMBL22921976 | 0.80 | HSD17B10 (0.74) | GMNNTP53POLBMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281058-B1 | FUNCTIONALIZED LONG-CHAIN DICARBOXYLIC ACIDS, AND THEIR USE FOR TREATMENT OF KIDNEY DISEASES | ESPERVITA THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250367149-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12396972-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12252467-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2025-03-18 | — | — | US | disclosed |
| US-12180151-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240417363-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2024-12-19 | — | — | US | disclosed |
| US-20240398737-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4464688-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | Espervita Therapeutics, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230111520-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230113853-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230007838-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11084773-B1 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210221765-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2021-07-22 | — | — | US | disclosed |
| US-20210024447-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230007838-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | GMNN 1919/4885TP53 522/4885POLB 2084/4885 |
| US-20230113853-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | AHR, PKD1, CFTR | GMNN 2249/4885TP53 2284/4885POLB 3266/4885 |
| US-20210221765-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | GMNN 1947/4885TP53 523/4885POLB 2088/4885 |
| US-20250367149-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | GMNN 1947/4885TP53 523/4885POLB 2088/4885 |
| US-11084773-B1 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | GMNN 1947/4885TP53 523/4885POLB 2088/4885 |
| US-12396972-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | GMNN 2249/4885TP53 2284/4885POLB 3266/4885 |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | GMNN 1975/4885TP53 597/4885POLB 2007/4885 |
| US-20230111520-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | GMNN 1975/4885TP53 597/4885POLB 2007/4885 |
| US-20210024447-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | GMNN 1947/4885TP53 523/4885POLB 2088/4885 |
| US-20240398737-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | AHR, PKD1, CFTR | GMNN 2249/4885TP53 2284/4885POLB 3266/4885 |
| US-20220402851-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | GMNN 1919/4885TP53 522/4885POLB 2084/4885 |
| US-12252467-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | GMNN 1947/4885TP53 523/4885POLB 2088/4885 |
| US-12180151-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | GMNN 1947/4885TP53 523/4885POLB 2088/4885 |
| US-20240417363-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | CPT1A, PPARG, PC | GMNN 1947/4885TP53 523/4885POLB 2088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.